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Fasting in Ramadan is obligatory for all healthy 
Muslim adults. No food or drink may be consumed 
between dawn and sunset [1]. Strictly speaking, 
the fast of Ramadan is a period of “intermittent 
fasting” or daily cycles of “alternating” fasting and 
feeding periods. The periods of the fasting and 
feeding vary by the geographical locations and by 
time of the year. During the month of Ramadan, 
there are two main meals in most Moslem 
communities. These are commonly referred to by 
their Arabic origin, namely  the “Iftar” (i.e. break of 
fast immediately after sunset) and “Sohur or 
Suhoor” (i.e. pre-dawn meal). As the Islamic 
calendar year is lunar, Ramadan (the ninth month) 
therefore starts approximately 10 days earlier each 
year on the Gregorian calendar. This year, 2007, 
Ramadan is likely to start between 12
th  and 14
th 
September.  
Certain groups are exempt from fasting 
temporarily or permanently including the sick, the 
elderly, the travellers and the expecting and 
nursing mothers [1]. However, many of those who 
are exempt may wish to observe the fast [2]. It is 
the responsibility of the medical professional to 
empower patients to make an informed choice 
and, if possible, an evidence-based decision.    
There are several studies on the changes 
observed in clinical, body composition, and 
biochemical parameters during the fasting month 
of Ramadan in healthy subjects and in various 
medical conditions. The EPIDIAR Study was the 
largest study reported involving 1,070 patients with 
type 1 diabetes and 11,173 patients with type 2 
diabetes [2].  Less than 50% of the whole 
population changed their treatment and 
hypoglycaemia was the only observed event.   
There are also a few studies which evaluated 
specific management modalities in those patients 
with diabetes who observed the fast [3-5]. These 
have been adequately summarised and discussed 
in previous review articles, expert opinion 
statements, and conferences proceedings over the 
last two decades [6-13]. A further detailed 
summary and critical appraisal of these studies is 
outside the scope of this article.  Our aim here is to 
present a practical approach to the assessment of 
diabetic patients before Ramadan and provide a 
guide on how to adjust the life style and medical 
management appropriately should the patient wish 




Management of people with diabetes during 
Ramadan: 
Organizational Issues 
The management of diabetes during Ramadan 
fasting should be considered well in advance of 
the holy month. Diabetes care departments should 
have comprehensive strategy meetings a few 
months before Ramadan. Many patients would 
have developed their own opinions and 
established their practices of amending their 
diabetes care management plans from previous 
personal experience. Patients attending diabetic 
clinics should be encouraged to seek advice 
before considering fasting the month of Ramadan 
[13]. However, poor knowledge about Ramadan 
and fasting and its management have been 
described among some health care professionals 
[14]. For patients, leaflet and booklets containing 
information and advice about Ramadan fasting for 
people with diabetes ought to be available in the 
waiting areas of diabetic clinics at least 3 months 
before the month starts (Figure 1). Special classes 
may need to be considered to enhance self-
management during this month [15]. Media 
presenters of health programmes and healthcare 
journalists should prepare such educational 
programmes in advance of the month of 
Ramadan. Expert doctors should take the time to 
give interviews preferably jointly with Imams to 
offer clear and authoritative views and respond to 
all commonly asked questions. In the clinical 
settings, doctors should have a clear 
understanding of the religious ruling on fasting to 
give their advice with confidence.  
 
The pre-Ramadan consultation 
Managing the individual patient with diabetes 
during Ramadan poses a major challenge. 
Patients and clinicians are confronted with the 
dilemma whether to fast or not. The caring 
physicians should approach this issue with great 
sensitivity.  They should be familiar with the 
religious rulings and cite these appropriately. They 
should also be very familiar with the rationale of 
current guidelines on who may be allowed to fast. 
Doctors should have an up to date working 
knowledge on practical management of diabetes 
should fasting be allowed.  
There are two questions that need to be 
answered. Firstly, when to advise against fasting? 
and secondly what is the optimal therapeutic 
regimen? Patients with type 1 and type 2 diabetes 
who are allowed or choose to fast should be given 
specific information on fasting and 
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recommendations on therapeutic changes. They 
should be warned against skipping meals, taking 
medication irregularly or night time gorging. A 
model content of the consultation is shown in 
Table 1.  This year we started to display Ramadan 
posters and distribute information leaflets from the 
end of June (Figure 1).  
 
Table 1. A proposed model pre-Ramadan consultation 
for diabetic persons who intend to fast. (modified from 
references 7 and 10) 
Timing of the consultations 
• Within 3 months before the start of fasting. 
 
Objectives of the consultation 
• To establish safety and appropriateness of fasting. 
• To propose life style programme. 
• To modify drug treatment regimen during Ramadan. 
• To suggest a home blood glucose monitoring plan 
and event-monitoring Ramadan diary. 
 
Contents of the consultation 
• Reflection on patien’ts previous experiences 
(previous fasting, amendments of medications and 
extent of success with fasting and any problems 
encountered). 
• Assessment of physical well being. 
• Assessment of metabolic control: symptoms; blood 
glucose profiles and HbA1c. 
• Adjustment of the diet protocol for Ramadan fasting. 
• Adjustment of the drug regimen  (e.g. change long-
acting hypoglycaemic drugs to short-acting drugs to 
prevent hypoglycaemia). 
• Agreeing the target pre-prandial and postprandial 
glucose levels. 
• Encouragement of continued appropriate physical 
activity. Ensuring ability to recognize warning 
symptoms of dehydration and hypoglycaemia, and 
other possible complications. 
• Supply educational material on fasting and 
Ramadan. 
• Provide a contact information and ensure availability 
of walk-in services during Ramadan should problems 
occur. 
• To arrange a post-Ramadan appointment to reflect 
on successes and short-comings. 
 
Possible obstacles 
• Failure to attend by patients. 
• Lack of resources such as printed materials. 
• Shortage of time in the pre-Ramadan clinic. 
• Lack of adequate knowledge or experience by 
consulting staff e.g. inexperienced doctors or 
educators. 
 
When to advise against fasting?  
The major concerns associated with fasting in 
patients with diabetes are shown in Table 2. These 
concerns need to be considered when the advice 
in favour of or against fasting is being addressed. 
There are widely accepted consensus criteria for 
advising against fasting  (Table 3). An alternative 
approach proposed  is a more elaborate 
stratification system to categorize risk in patients 
with type 1 or type 2 diabetes who fast during 
Ramadan into very high, high, moderate and low 
[11].  Very high risk included those with severe 
hypoglycaemia within the last 3 months prior to 
Ramadan, patients with a history of recurrent 
hypoglycaemia, patients with hypoglycaemia 
unawareness, patients with sustained poor 
glycaemic control, ketoacidosis within the last 3 
months prior to Ramadan, type 1 diabetes, acute 
illness, hyperosmolar hyperglycaemic coma within 
the previous 3 months, patients who perform 
intense physical labour, pregnancy, and patients 
on chronic dialysis. High risk patients included 
those with moderate hyperglycaemia (average 
blood glucose between 150 and 300 mg/dl, A1C 
7.5–9.0%), patients with renal insufficiency, 
patients with advanced macrovascular 
complications, people living alone that are treated 
with insulin or sulfonylureas, patients living alone, 
patients with comorbid conditions that present 
additional risk factors, old age with ill health and 
those on drugs that may affect mentation. 
 
Table 2.  Major risks associated with fasting in patients 
with diabetes and their potential mechanisms (modified 
from references 11)* 
•  Hypoglycaemia:  Particularly increased in type 1 
patients and in insulin-treated type 2 patients.  This is 
due to restricted carbohydrate intake against ongoing 
action of previously admistered insulin/long acting 
oral hypoglycaemic agent. 
• Hyperglycaemia:  Mainly in the evening time 
complicating gorging and in day day time 
complication overzealous reduction of the doses of 
insulin or oral hypoglycaemic agents. 
• Diabetic ketoacidosis or hyperglycaemic 
hyperosmolar states: due to absolute or relative 
insulin deficiency or due to associated intercurrent 
illness.  
• Dehydration and increased risk of thrombosis: 
particularly in the poorly controlled or the elderly and 
in environments of high temperatures particularly 
when fasting period is long.  
• Risk to the foetus: complicating any of the above. 
These form the basis for advice against fasting in 
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Table 3.  Widely-accepted criteria to advise against 
fasting in patients with Diabetes. (modified from 
references 6-10)* 
• All unstable "brittle" type 1 diabetic patients. 
• Unstable newly diagnosed type 1 or type 2 patients. 
• Diabetic patients known to be non-compliant in 
terms of following advice on diet and drug regimens 
and daily activity. 
• Diabetic patients with serious complications such as 
acute coronary syndromes, uncontrolled hypertension 
and renal failure. 
• Patients with a recent history of diabetic 
ketoacidosis or hyperosmolar states until stable. 
• All pregnant diabetic patients. 
• Diabetic patients with inter-current infections. 
• Elderly patients with any degree of cognitive 
dysfunction. 
• Two or more previous episodes of hypoglycaemia 
and/or hyperglycemia during Ramadan. 
• Hypoglycaemic unawareness. 
• Unstable epilepsy (particularly if fits have been 
precipitated by hypoglycaemia in the past). 
* Some workers considered these separately for type 
1 and type 2 patients and further subdivided them as 
absolute contraindications or relative contraindications 
or even more elaborate risk stratification (see text). 
 
Moderate risk was exemplified by the well-
controlled patients treated with short-acting insulin 
secretagogues,   whereas well-controlled patients 
treated with diet alone, metformin, or a Glitazone 
who are otherwise healthy were deemed to have a 
low risk [11]. Because of the religious nature of the 
fast, the use of the terms “indicated” and 
“contraindicated” were deemed to be inappropriate 
[11]. These are based on the practical translation 
of the Quran teaching that “Muslims should not put 
themselves at risk by fasting” [1].  However, many 
diabetic subjects choose to fast and the physician 
should be sympathetic and sensitive to their 
convictions and try  to work out a programme that 
will minimise the risk.  The physician should agree 
on a strategy when to break the fast and when to 
terminate it, e.g. if more than one hypoglycaemic 
episode occurs then no further attempts to fast 
should be made (Table 3).  
 
Life style modifications 
Life style should be re-enforced before and 
during Ramadan (Table 4). Lack of careful 
attention to diet during the ‘non-fasting’ night time 
period with excessive gorging, or compensatory 
eating of carbohydrates and fatty foods, 
contributes to poor control and wide excursions in 
blood glucose and weight gain in the well 
controlled patient. Therefore, patients should be 
encouraged to maintain their good dietary habits 
and to resist any temptation to break their dietary 
restrictions, as during Ramadan, social functions 
are frequent and food is a common way of 
hospitality. Benefits from Ramadan fasting seem 
to appear only in patients who maintain their 
appropriate diets. Thus, in order to optimise 
glycaemic control, individuals with diabetes must 
be reminded to abstain from the high-calorie foods 
prepared during this month. Regular light to 
moderate exercise during Ramadan fasting can be 
tolerated and is safe in type 2 patients. Therefore, 
light to moderate exercises may continue 
throughout the fast either in the morning or at 
night well after breaking the fast. It is probably 
prudent to avoid exercise in the final few hours of 
the fast when the risk of hypoglycaemia is 
predictably maximal particularly in insulin-treated 
patients [2].  
 
Table 4. Example of guidance for self-management 
for fasting diabetic patients to be included in posters 
and leaftets to support the consultations (Modified from 
reference 9) 
• Arrange your pre-Ramadan fasting 
consultation with the doctor or diabetes 
educator to review your control and feasibility of 
fasting safely and make notes of the changes 
you need to do during the fast.  
• Record weight daily and inform doctor of a 
change of more than 2kg. 
• Learn the warning symptoms of 
hyperglycaemia and hypoglycaemia 
• Take medication regularly as instructed. 
• Continue gentle to moderate physical activity 
particulatly in the evening. 
• Do not overeat after the fast is broken and 
minimise eating sweet or fatty foods. 
• Record daily diet intake to help prevent 
excessive or very low consumption.  
• If a complication occurs, break the fast 
immediately and seek medical help. Resist any 
temptation to persevere with the fasting till end 
of the day. 
• Test blood glucose before and 2 hours after 
Iftar, before Sohur, and at mid day. 
• At the end of Ramadan, reflect on your 
achievements and problems and feed back to 
the doctor/diabetes educator. 
 
Modification of drug regimens 
A. Type 2 diabetes 
Patients with type 2 diabetes can be controlled 
by adhering to similar drug regimens to the pre-
fasting period with the morning oral 
hypoglycaemic given at the break of the fast and 
the pre-dinner dose is usually reduced by 25–50% 
and given pre-Sohur. Anecdotally, use of 
Nateglinides with Iftar may produce less 
excursions of blood glucoses after Iftar either as a 
replacement to sulphonylureas or new addition to 
metformin of Glitazones.  
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Metformin could be given post-Iftar and Sohur 
but some patients may not tolerate the post-Sohur 
dose because of the gastrointestinal side-effects. If 
a slow-release preparation of metformin is 
available, the whole daily dose may be taken 
altogether after Iftar.  
Patients on insulin and sulphonylureas 
combination should take their basal insulin 
(Isophane, Glargine or Detimer) about 10 pm to 12 
midnight and the oral hypoglycaemic agents taken 
at Iftar.  
Although there are no data on the use of newer 
anti-diabetic agents during Ramadan, it would 
seem sensible to take the Glitazones with the 
evening meal as they are normally taken once 
daily. Patients on the oral Gliptins would probably 
be better taking their single daily dose at Iftar.   
Exenatide injections should be taken twice before 
Iftar and before Suhor.  It is likely that the Gliptins 
and incretin mimetics will specifically help reduce 
the post-iftar blood hyperglycaemia. However, 
evidence is lacking. 
 
 
Figure 1. Four examples of educational material on 
diabetes during  Ramadan fast from Abu Dhabi, Qatar, 
Jordon and Morocco. 
 
B. Type 1 diabetes 
If a type 1 diabetic individual chooses to fast, 
then great care should be taken to monitor and 
adjust the dose of insulin accordingly.  
Those on intensive insulin treatment should 
receive their long-acting basal insulin (such as 
Glargine and Detimer) at Iftar or at the usual time 
of 10 pm- 12 mid night (Isophane Insulin should be 
given as usual before bedtime). The dose of basal 
insulin needs to be adjusted according to blood 
glucose levels between mid-day and Iftar time. 
The short-acting insulin or rapid-acting insulin 
analogue at Iftar and Sohur times. The doses of 
these can be adjusted according to the amount of 
food consumed; previous experiences and blood 
glucoses measured 2-3 hours after iftar 
(conveniently after Isha prayers). For assessment 
of the pre-Sohur insulin doses, blood glucose can 
be measured between 11-12 mid day  
Those on conventional twice daily insulin 
regimens should take their usual morning dose 
before Iftar and their usual evening dose before 
Sohur. However, the latter needs to be adjusted 
so that the fast-acting component remains the 
same and the intermediate acting insulin is cut by 
50% or omitted.  
Those on pre-mixed insulin such as 30/70 or 
25/75 preparations (such Mixtard of Novo Nordisk 
or Humulin M series from Eli Lilly) should have 
their morning dose before the Iftar in the same or 
even greater dose. However the pre-Sohur dose 
should be reduced or substituted with shorter 
acting insulin only.  
Some patients on insulin pump therapy 
managed to fast safely by adjusting their basal 
insulin down during the fasting time.  
 
 
Figure 2. An example of a blingual poster for Diabetes 
and Ramadan Fast from Sheikh Khalifa Medical City, 
Abu Dhabi, UAE. The information is fairly basic and 
quite appropriate for a poster 
 
Conclusions 
In conclusion, the majority of physicians are of 
the opinion that Ramadan fasting is acceptable for 
well balanced type 2 patients conscious of their 
disease and compliant with their diet and drug 
intake. Islamic rules allow patients not to fast. 
However, if patients with diabetes wish to fast, it is 
necessary to advise them to undertake regular 
monitoring of blood glucose levels several times a 
day, to reduce the risk of hypoglycemia during 
daytime fasting or hyperglycemia during the night. 
Patients with type 1 diabetes who fast during 
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Ramadan may be better managed with fast- acting 
insulin.  Basic knowledge of carbohydrate 
metabolism in health and disease, of the standard 
principles of diabetes care and of pharmacology of 
various anti-diabetic drugs are essential to enable 
physicians to guide their patients through the 
month of Ramadan safely. The practical 
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